In chemical processes for producing pharmaceuticals, catalysts are a core technology that determines production speed and ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. Lower interest rates aided the biotech bounceback, as many companies in the sector rely on a ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on September ...

Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Cybin (CYBN). The reason why I want to go over this biotech next is because it is in the ...

CORAL GABLES, Fla. (AP) — CORAL GABLES, Fla. (AP) — Catalyst Pharmaceutical Partners Inc. (CPRX) on Wednesday reported fourth-quarter earnings of $52.7 million. On a per-share basis, the Coral Gables, ...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions. Neither ...